Intuitive Surgical Stock - Bank of America trims price target on margin concerns

Intuitive Surgical stock faces a cautious note from Bank of America, which has nudged its price target slightly lower while maintaining a Buy rating. On Wednesday, we look at the latest analyst stance and how it fits into the broader consensus.

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 16:46 CET. Details in the imprint.

Intuitive Surgical (US46120E6023) sits under slightly more cautious analyst scrutiny this week. Bank of America has trimmed its price target while reiterating a Buy rating, citing inflation-driven margin headwinds, according to a Bank of America update summarized by InsiderMonkey.

What Bank of America changed

Bank of America Securities analyst Travis Steed has lowered his price target on Intuitive Surgical from $520 to $515, while keeping a Buy recommendation in place. The revision reflects expectations that inflation will keep pressure on operating margins.

The update flags higher costs and reimbursement dynamics as key factors moderating margin expansion in the near term. Nonetheless, the maintained Buy rating underlines the house view that Intuitive Surgical’s growth prospects remain intact despite softer profitability assumptions.

How the call fits the wider analyst picture

Steed’s move is incremental rather than dramatic, trimming less than 1% from the prior price target. That suggests a fine-tuning of the model rather than a fundamental change in conviction on the company’s long-term trajectory.

Consensus data from major financial portals show that most covering analysts still rate Intuitive Surgical stock at Buy or Overweight, with a minority at Hold, underscoring broadly positive sentiment toward its procedure growth and installed base expansion.

Operational themes on this Wednesday

From an operational perspective, Intuitive Surgical is still leaning on procedure growth and system placements to drive revenue. Management has repeatedly highlighted utilization and recurring instruments and accessories revenue as core profitability levers in recent quarterly commentary.

Inflation and wage costs, however, are raising the bar for efficiency gains in manufacturing and servicing. For a capital-intensive, high-innovation business, that means tighter scrutiny from analysts on expense discipline and pricing power in upcoming earnings cycles.

What the company sells

Intuitive Surgical makes most of its money with the da Vinci robotic-assisted surgery system, including surgical robots, instruments, accessories and maintenance services. Hospitals and surgical centers use da Vinci platforms in procedures such as urology, gynecology and general surgery.

Where the stock trades today

The shares of Intuitive Surgical (US46120E6023) trade on the Nasdaq at $417.07 as of 06/17/2026, 14:30 ET.

Key facts on Intuitive Surgical stock

• Company: Intuitive Surgical, Inc.
• ISIN: US46120E6023
• WKN: 888024
• Ticker: ISRG
• Venue: Nasdaq
• Price (as of 06/17/2026, 14:30 ET): 417.07 USD
• Market cap: 148,000,000,000 USD (as of 06/17/2026)
• Sector / Industry: Health Care / Medical Devices
• Index membership: S&P 500, Nasdaq-100
• Next earnings date: 07/18/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.